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  73 
Abstract 74 
Objective: To identify prognostic factors for short-term survival of dogs that experienced 75 
seizures within seven days following surgical correction of single congenital extrahepatic 76 
portosystemic shunts (cEHPSS).  77 
Study Design: Multi-institutional retrospective study. 78 
Sample Population: Ninety-three client-owned dogs.  79 
Methods: Medical records at 14 veterinary institutions were reviewed to identify dogs that 80 
underwent surgical attenuation of a single cEHPSS from January 1st 2005 through February 81 
28th 2018 and experienced post-attenuation seizures (PAS) within seven days postoperatively. 82 
Logistic regression analysis was performed to identify factors associated with one month 83 
survival. Factors investigated included participating institution, signalment, shunt 84 
morphology, concurrent/historical conditions, presence of preoperative neurologic signs, 85 
presence of preoperative seizures, aspects of preoperative medical management, surgical 86 
details including method and degree of shunt attenuation, type of PAS (focal only or 87 
generalized +/- focal), drugs administered as part of the treatment of PAS, and development 88 
of complications during treatment of PAS.  89 
Results: Thirty (32.3%) dogs survived to 30 days. Seventy-six (81.7%) dogs experienced 90 
generalized PAS. Factors positively associated with short-term survival included having a 91 
history of preoperative seizures (p=0.004) and development of focal PAS only (p=0.0003). 92 
The majority of non-survivors were humanely euthanized due to uncontrolled or recurrent 93 
seizures. 94 
Conclusions: Dogs that experienced PAS that had a history of preoperative seizures and 95 
those that experienced focal PAS only had significantly improved short-term survival. 96 
Clinical Significance: The results of this study will help in the counseling of owners who 97 
seek treatment for PAS following surgical correction of cEHPSS.  98 
Introduction 99 
Development of post-attenuation seizures (PAS) is a well-recognized complication of surgical 100 
correction of portosystemic shunts in dogs,1-25 with often fatal consequences.1-3,8-10,12,15,18,21,22 101 
These seizures have an incidence of up to 4.7-8.1% in the recent literature,18,21,22,REDACTED and 102 
occur almost exclusively within five days postoperatively.1-25 The etiopathogenesis of PAS is 103 
not well understood. Proposed theories include a decline in systemic concentrations of 104 
endogenous benzodiazepines/benzodiazepine-like substances, hypoglycemia, electrolyte 105 
derangements (hypocalcemia and hypokalemia), hypoxemia, exacerbation of hepatic 106 
encephalopathy, an unknown perioperative metabolic event, sudden correction of an adapted 107 
to altered metabolic state, systemic hypertension, concurrent brain disease, intraoperative 108 
hypotension, and prolonged surgical and anesthetic times.2,3,9,10,21,23,26,26 However; none of 109 
these has been consistently identified in previous studies.1-25 For instance, PAS have been 110 
reported in the face of normal to only mildly elevated ammonia concentrations,2,7,9,10,17,20,22 and 111 
normal glucose7-10,17,20,21,23 and electrolyte concentrations.17,20 112 
 113 
Large-scale studies investigating risk factors for PAS are lacking.22 In a recent study by 114 
Strickland et al, increasing age and the presence of hepatic encephalopathy immediately 115 
preoperatively were identified as risk factors for postoperative neurologic signs and seizures.22 116 
Occurrence of PAS has not been definitively shown to be associated with shunt morphology 117 
(intra- or extrahepatic, or individual sub-morphologies), presence of preoperative seizures, or 118 
method or degree of shunt attenuation.2,3,6,9,11,14-19,21,22 Certain breeds have been suggested as 119 
being at greater risk of PAS including Pugs,6,9,23 Maltese terriers,1,2 and Jack Russell terriers.14  120 
 121 
On the basis of a limited number of case reports, small case series and isolated cases within 122 
retrospective studies, a guarded prognosis is typically provided following development of 123 
PAS.1-3,8-10,12,15,18,21,22 The largest published cohort of dogs affected by PAS is in a study by 124 
Strickland et al,22 which described 12 dogs with PAS. In that study,22 which included dogs with 125 
cEHPSS and cIHPSS, only seven of 12 dogs that experienced PAS survived to discharge. A 126 
number of studies; however, have reported a more favorable prognosis.7,17,20,21 In one study,21 127 
dogs that experienced PAS that had a history of preoperative seizures demonstrated improved 128 
survival compared with those that had not. There are also reports of a more favorable outcome 129 
following treatment of PAS with administration of continuous rate infusion (CRI) of 130 
propofol.7,17,20 A limitation of these reports; however, is their small size and the fact that other 131 
anti-epileptic drugs were administered concurrently with propofol CRI, which makes 132 
interpretation difficult.  133 
 134 
The objective of this study was to identify prognostic factors for short-term survival of dogs 135 
that experienced PAS within seven days following surgical correction of single cEHPSS. We 136 
hypothesized that having received prophylactic LEV, treatment of PAS with propofol CRI, 137 
dogs that experienced PAS/underwent surgery in the second half of the study period, and 138 




  143 
Materials and Methods 144 
Inclusion and exclusion criteria 145 
Medical records at 14 institutions were retrospectively reviewed to identify 146 
dogs that underwent surgical attenuation (suture ligation [SL], thin film banding [TFB], or 147 
ameroid ring constrictor [ARC] placement) of a single cEHPSS from January 1st 2005 148 
through February 28th 2018 and experienced PAS within seven days postoperatively. 149 
Exclusion criteria included dogs with cIHPSS, dogs that did not undergo shunt attenuation 150 
due to apparent concurrent portal vein aplasia; and dogs that were lost-to-follow-up prior to 151 
30 days postoperatively. Dogs that experienced onset of seizure activity after seven days 152 
post-attenuation were excluded.  153 
 154 
Data collection 155 
Data retrieved from medical records of dogs that met inclusion criteria included breed, age, 156 
sex/neuter status, and bodyweight at surgery; year of surgery; shunt morphology (portocaval, 157 
portoazygous or portophrenic); concurrent/historical conditions at presentation; presence and 158 
type of preoperative neurologic signs and seizures; abnormal preoperative physical 159 
examination findings; method of shunt identification (abdominal ultrasound, computed 160 
tomography angiography [CTA], magnetic resonance imaging [MRI], intraoperative 161 
portovenography [IOPV], nuclear scintigraphy); details of preoperative medical management; 162 
prophylactic LEV or other anti-seizure medication(s); method- (SL, TFB or ARC) and degree 163 
(complete, partial, or none) of acute intraoperative shunt attenuation; timing and type of PAS 164 
(focal only or generalized +/- focal), electrolyte (sodium, potassium and chloride), glucose 165 
and ammonia concentrations around time of PAS occurrence; anti-seizure medication(s) 166 
administered as part of treatment of PAS; complications experienced during treatment of 167 
PAS; and whether the dog survived to one month. Regarding preoperative medical 168 
management, dogs were recorded as having received at least one week’s duration of 169 
preoperative lactulose or not and at least one week’s duration of antimicrobial(s) or not. 170 
Preoperative diet type was also recorded. Dogs were divided into four groups concerning 171 
prophylactic treatment with LEV: received no LEV (LEV-); received LEV at >20mg/kg 172 
every eight hours (TID) for >24 hours preoperatively or 60mg/kg intravenous loading dose of 173 
LEV perioperatively, and continued at >20mg/kg TID postoperatively (LEV1); received LEV 174 
at <20mg/kg TID, for <24 hours preoperatively, or continued at <20mg/kg TID 175 
postoperatively (LEV2); and received LEV postoperatively only (but prior to postoperative 176 
seizure activity) according to the same preoperative protocol of group LEV1 (LEV3). Short-177 
term survival was defined as survival to 30 days. For dogs that did not survive to 30 days, 178 
whether the dog had died naturally or been humanely euthanized and the cause/reason were 179 
recorded. A complication was defined as any unanticipated event that altered the course of 180 
PAS treatment. 181 
 182 
Statistical analyses 183 
Continuous variables were tested for normality using graphical methods, skewness, kurtosis 184 
and Shapiro-Wilk tests. Normally and non-normally distributed continuous variables were 185 
presented as mean and standard deviation (SD) and median and range, respectively. Categorical 186 
variables were presented as frequency and percentages (with 95% CI). Comparison of 187 
electrolyte, glucose and ammonia concentrations between survivors and non-survivors and 188 
dogs with and without a history of preoperative seizures were made using the independent 189 
samples t-test or Mann Whitney U-test depending on normality of the data. Univariable logistic 190 
regression analysis was performed to assess for factor association with one month survival. 191 
Factors assessed included contributing institution, breed, sex/neuter status, age, and 192 
bodyweight at surgery; year of surgery; shunt morphology; presence of preoperative 193 
neurological signs; presence of preoperative seizure activity; presence concurrent/historical 194 
conditions at presentation; whether the dog received a minimum of one week’s duration of 195 
preoperative lactulose, whether the dog received a minimum of one week’s duration of 196 
antimicrobial(s); LEV group (LEV-, LEV1, LEV2 or LEV3); method of shunt attenuation, 197 
degree of acute intraoperative shunt attenuation (complete, partial or none); whether the dog 198 
developed generalized or focal PAS only, and whether the dog experienced a complication 199 
during treatment of PAS. The second half of the study period was defined as January 1st 2012 200 
onwards. Additional factors assessed included treatment of PAS with propofol CRI, alfaxalone 201 
CRI, benzodiazepine(s), LEV, phenobarbital, potassium bromide, alpha-2 agonist, 202 
gabapentin/pregabalin, flumazenil, and mannitol. Multivariable logistic regression analysis 203 
was performed to assess all variables identified with p<0.2 in the univariable analysis. 204 
Backwards selection was used with a retention alpha of 0.05 for variables to be retained in the 205 
model. This allowed calculation of adjusted odds ratios and 95% CI. The statistical analysis 206 














Ninety-three dogs were included in the study. Details of 75 dogs are the subject of another 221 
report.REDACTED Details of 16 dogs have partially been reported previously.17,18,20,21 222 
 223 
Signalment  224 
Breeds included mixed breed (n=18), Yorkshire terrier (n=15), Bichon Frise (n=12), Pug 225 
(n=9), Shih Tzu (n=8), Maltese terrier (n=6), Jack Russell terrier (n=6), Miniature Schnauzer 226 
(n=5), Chihuahua (n=4), Dachshund (n=3), West Highland white terrier (n=2), and one each 227 
of Norfolk terrier, Border terrier, Brussels Griffon, Coton De Tulear and Setter. There were 228 
31 (33.3%) spayed females, 13 (14.0%) intact females, two (2.2%) unspecified females, 28 229 
(30.1%) castrated males, and 19 (20.4%) intact males. Median (range) age was 34 (5-124) 230 
months. Median (range) weight was 6 (1.4-21.0) kg.  231 
 232 
Year of surgery 233 
Thirty-three (35.5%) dogs experienced PAS from January 2005 through December 2011 (first 234 
half of study period), 60 (64.5%) experienced PAS from January 2012 through February 2018.  235 
 236 
Historical neurologic signs and seizures 237 
Preoperative neurologic signs were recorded in 73/93 (78.5%) dogs. Preoperative seizures 238 
were recorded in 16/93 (17.2%) dogs. The most common neurologic signs included reduced 239 
mentation (n=46), pacing/wandering/compulsive walking (n=15), ataxia (n=12), abnormal 240 
behavior/behavior change (n=11), head pressing (n=9), hypersalivation/drooling (n=9), 241 
circling (n=8), disorientation (n=5), and four each of increased/inappropriate sleeping/sleepy, 242 
apparent blindness, and weakness. 243 
 244 
Concurrent/historical conditions at presentation 245 
Concurrent/historical conditions at presentation were recorded in 27/93 (29.0%) dogs and 246 
most commonly included urolithiasis (n=19); urinary tract infection (n=8); cardiac murmur 247 
(n=4); unspecified brachycephalic airway syndrome; and one each of urinary 248 
sediment/crystalluria, pattern baldness, distichiasis, and cryptorchidism. Two dogs had 249 
previously undergone cEHPSS attenuation, seven and 16 months prior, respectively, but did 250 
not experience PAS following initial surgery.  251 
 252 
Method of shunt identification and morphology 253 
Shunts were identified preoperatively by ultrasonography (n=75), CTA (n=31), nuclear 254 
scintigraphy (n=3), and/or MRI (n=1). Seventeen dogs underwent IOPV. Shunt morphology 255 
was available for 89/93 (95.7%) dogs and included portocaval (n=67), portoazygous (n=16), 256 
and portophrenic (n=6). 257 
 258 
Preoperative medical management 259 
Ninety-one (97.8%) dogs received preoperative medical management, which included 260 
combinations of antimicrobial(s), lactulose and a protein-restricted diet. One dog did not 261 
receive preoperative medical management. For the remaining dog, this information could not 262 
be confirmed. Seventy-eight (83.9%) dogs received at least one week of preoperative 263 
antimicrobial. Eighty-one (87.1%) dogs received at least one week of preoperative lactulose. 264 
Fifty-seven dogs received a prescription hepatic diet, eight received an unspecified protein-265 
restricted diet, five received a protein-restricted renal diet. Other diets included a 266 
hypoallergenic diet (n=3), vegetarian diet (n=2), homemade protein-restricted diet (n=2), and 267 
one each received a gastrointestinal diet and homemade chicken and vegetable diet. For the 268 
remaining dogs, the type of diet was not recorded.  269 
 270 
Prophylactic LEV or other anti-seizure medication(s) 271 
Fifty (53.8%) dogs had received prophylactic LEV. One of these dogs had received 272 
additional prophylactic treatment with phenobarbital (3 mg/kg every 12 hours) and potassium 273 
bromide (8 mg/kg every 24 hours) for 3 months preoperatively. Forty-three (46.2%), 22 274 
(23.7%), 25 (26.9%) and three (3.2%) dogs were included in groups LEV-, LEV1, LEV2 and 275 
LEV3, respectively. 276 
 277 
Preoperative physical examination findings 278 
Preoperative physical examination findings were available for 86/93 (92.5%) dogs. Abnormal 279 
findings were recorded in 48/86 (55.8%) dogs and most commonly included reduced/altered 280 
mentation/lethargy (n=22), underweight/suboptimal body condition (n=16), small stature 281 
(n=7), ataxia (n=6), circling (n=4), pacing/wandering (n=3), and cardiac murmur (n=3).  282 
 283 
Method and degree of shunt attenuation 284 
Shunts were attenuated using TFB (n=36, partial attenuation [n=20], no attenuation [n=16]); 285 
ARC (n=33, no attenuation [n=33]); SL (n=23, complete attenuation [n=20]; partial 286 
attenuation [n=3]); and combination of TFB and suture (n=1, partial attenuation [n=1]). 287 
 288 
Type and timing of post-attenuation seizures 289 
Seventy-six (81.7%) dogs were recorded as having developed generalized PAS, while 17 290 
(18.3%) developed focal PAS only. Of the 76 dogs that experienced generalized PAS, 13 291 
(17.1%) were recorded as having experienced focal PAS that later progressed to generalized 292 
despite treatment. Post-attenuation seizures commenced after a median (range) of 48 (3-144) 293 
hours postoperatively. Seventy-three (78.5%) dogs developed PAS while hospitalized. 294 
Twenty (21.5%) dogs displayed neurologic signs/commenced seizure activity post-discharge. 295 
 296 
Electrolyte, glucose and ammonia concentrations at the time of post-attenuation 297 
seizures 298 
Electrolyte, glucose and ammonia concentrations overall (when available), among survivors 299 
and non-survivors, and dogs with and without a history of preoperative seizures are listed in 300 
Table 1. No significant differences in these parameters were identified between survivors 301 
versus non-survivors or dogs with versus without a preoperative history of seizures (Table 1). 302 
 303 
Treatment of post-attenuation seizures 304 
Ninety (96.8%) dogs received treatment for PAS. One dog that experienced focal PAS only 305 
did not receive any anti-seizure treatment. A further dog that experienced focal PAS only did 306 
not receive any additional treatment apart from continued administration of LEV. One dog 307 
that experienced a generalized seizure at home was already receiving LEV but did not receive 308 
any additional treatment. Specific details of drugs administered as part of the treatment of 309 
PAS were available for all but one dog. One dog that was receiving prophylactic LEV 310 
experienced generalized PAS treated by the primary veterinarian. Specific details regarding 311 
additional anti-seizure medication(s) administered were not available. Of 20 (21.5%) dogs 312 
that commenced seizure activity post-discharge, nine (45.0%; 9.7% of all dogs) were treated 313 
for PAS by their local veterinarian; eight (40.0%; 8.6% of all dogs) were re-presented to the 314 
participating institution; two (10.0%) were treated initially by the local veterinarian and 315 
subsequently re-presented; while the remaining dog was treated for generalized PAS with 316 
continued administration of LEV by the owner at home. 317 
 318 
Focal seizures only 319 
Dogs that experienced focal PAS only were treated with LEV (n=15; ten were already 320 
receiving prophylactic LEV; LEV1 [n=6], LEV2 [n=4]), benzodiazepine(s) (n=9), propofol 321 
CRI (n=6), phenobarbital (n=6), potassium bromide (n=3), flumazenil (n=2), alpha-2 agonist 322 
(n=1), and/or gabapentin (n=1). One dog was taken back to surgery to have the thin film band 323 
removed due to concerns over possible portal hypertension; moderate liver congestion was 324 
noted at surgery but without congestion of mesenteric vessels. The dog was euthanized 325 
intraoperatively at the request of the owners.  326 
 327 
Generalized seizures 328 
Dogs that experienced generalized PAS were treated with LEV (n=49; 34 were already 329 
receiving prophylactic LEV; LEV1 [n=16], LEV2 [n=21], LEV3 [n=3]), phenobarbital 330 
(n=49; one dog was already receiving prophylactic phenobarbital), propofol CRI (n=43), 331 
benzodiazepine(s) (n=36), mannitol (n=16), potassium bromide (n=10; one dog was already 332 
receiving prophylactic potassium bromide), alpha-2 agonist (n=7), alfaxalone CRI (n=3), 333 
and/or gabapentin/pregabalin (n=3).  334 
 335 
Development of complications during treatment of post-attenuation seizures 336 
Sixteen (17.2%) dogs experienced one or more significant complication(s) during treatment 337 
of PAS within 30 days postoperatively (Table 5). The most common complication was 338 
development of aspiration pneumonia.  339 
 340 
Short-term survival 341 
Thirty (32.3%) dogs survived to 30 days. Of those that did not survive, 50 (79.4%) were 342 
humanely euthanized, nine (14.3%) died, one (1.6%) suffered cardiorespiratory arrest and 343 
was successfully resuscitated but later euthanized. For the remaining three (4.8%) dogs, it 344 
was not recorded whether they had died or been euthanized. The most common reason for 345 
euthanasia was uncontrolled or recurrent seizures (Table 5). Median (range) survival time of 346 
non-survivors was 4 (1-20) days (recorded as 2-3 weeks postoperatively [n=1]). Of those that 347 
survived to 30 days, 16 experienced generalized PAS, 14 experienced focal PAS only. Sixty 348 
dogs that did not survive to 30 days experienced generalized PAS, while three experienced 349 
focal PAS only. Cause of natural death and reasons for humane euthanasia are listed in Table 350 
5.  351 
  352 
Prognostic factors associated with short-term survival 353 
Results of univariable analysis are summarized in Tables 2 and 3. Prophylactic treatment with 354 
LEV, surgery performed in the second half of the study period, and treatment of PAS with 355 
propofol CRI were not associated with short-term survival. Factors associated with short-term 356 
survival in the multivariable analysis included having a history of preoperative seizures 357 
(p=0.004) and type of PAS (p=0.0003) (Table 4). Dogs with a history of preoperative 358 
seizures had a 7.6-fold (95% CI: 1.9-30.3) increased odds of survival to 30 days compared 359 
with those without, with adjustment for PAS type. Dogs that developed focal PAS only had 360 
significantly increased odds of survival (OR=14.4 (95% CI: 3.4-60.2)) compared with those 361 




  366 
Discussion 367 
The main findings of this study are: (1) affected dogs that had a history of preoperative seizures 368 
and those that experienced focal PAS only had significantly increased odds of survival to 30 369 
days, and (2) having received prophylactic treatment with LEV, treatment of PAS with 370 
propofol CRI, and having undergone surgery/experienced PAS in the second half of the study 371 
period were not associated with improved short-term survival.  372 
 373 
In a recent study by Brunson et al,21 dogs that experienced PAS that had a history of 374 
preoperative seizure activity had a 7-fold increased probability of survival compared with those 375 
that had not. Similarly, in our study, such dogs had an almost 8-fold increased odds of survival 376 
to 30 days. One possible explanation for this is that PAS experienced by both of these subsets 377 
of dogs have a different etiopathogenesis or that some dogs with a history of preoperative 378 
seizure activity have continuation of these seizures postoperatively. We did not find support 379 
for hyperammonemia to be responsible for PAS in such affected dogs in our study, which is 380 
consistent with reports by several other investigators.2,7,9,10,17,20,22 It is well recognized that 381 
ammonia concentrations and severity of encephalopathy do not always correlate, emphasizing 382 
the importance of other neurotoxic substances.27 In a study by Strickland et al,22 the presence 383 
of hepatic encephalopathy immediately preoperatively was identified as a risk factor for PAS; 384 
however, similar to our results, postoperative ammonia concentrations were normal to mildly 385 
elevated in all dogs for whom it was available.  386 
 387 
Dogs that experienced focal PAS only in our study had 14.4-fold increased odds of short-term 388 
survival compared with those that experienced generalized PAS. Whether focal PAS in such 389 
affected dogs represent a less aggressive form of neurologic dysfunction, has a different 390 
etiopathogenesis, or would have progressed to generalized PAS without anti-seizure treatment 391 
is unknown. Seventeen percent of dogs that developed generalized PAS in our study were 392 
recorded as having experienced initial focal PAS, which highlights that these may be a 393 
precursor to generalized PAS in some cases. In a study by Mehl et al,15 all dogs that experienced 394 
focal PAS only survived to discharge, while all those that experienced generalized PAS within 395 
seven days postoperatively died during hospitalization. The majority of dogs that failed to 396 
survive to 30 days in our study were humanely euthanized, most commonly due to uncontrolled 397 
or recurrent seizures (Table 5). It is possible that factors such as client unwillingness to continue 398 
treatment, financial constraints, or an attending clinician’s perception of a poor prognosis for 399 
neurologic recovery may have significantly influenced the decision to euthanize. It may be 400 
anticipated that generalized PAS may be more challenging to abolish, more distressing for the 401 
pet owner to observe, associated with a greater treatment cost and the perception of a poorer 402 
prognosis for recovery, all of which may provoke a decision to euthanize.  403 
 404 
Only one third of dogs that experienced PAS in our study survived to 30 days, which is in 405 
agreement with previous reports of 0-53.8% in the literature.2,3,9,15,18,21,22 The large proportion 406 
(81.7%) of dogs in our study that experienced generalized PAS will have strongly influenced 407 
the low short-term survival rate as such dogs had significantly decreased odds of survival in 408 
the multivariable analysis.  409 
 410 
We hypothesized that having undergone surgery/experienced PAS in the second half of the 411 
study period would be positively associated with short-term survival. This was based on the 412 
premise that with greater experience in treating PAS and advances in critical care medicine, 413 
short-term survival would be improved. This was not supported by the results of our study. 414 
Possible explanations for this may be related to factors such as a perceived poor prognosis for 415 
neurologic recovery, factors outside of the control of the attending clinician including client 416 
unwillingness to pursue treatment and financial constraints, and the overall infrequent 417 
occurrence of PAS. In our study, the maximum number of cases of PAS seen by any institution 418 
in a single year was four, with most institutions seeing a maximum of one to two cases per 419 
year.  420 
 421 
Administration of several anti-epileptic drugs has been described for the treatment of PAS in 422 
previous reports including benzodiazepines,2,3,9-12,14,15 barbiturates,2,3,6-12,14,15 and 423 
propofol.7,10,14,17 There are; however, no large-scale studies which compare outcomes of 424 
affected dogs treated with various anti-epileptic drugs, likely due to the infrequent occurrence 425 
of these seizures and subsequent small case numbers within individual institutions.22 In our 426 
study, none of these anti-epileptic drugs, including propofol CRI, was associated with short-427 
term survival. On the basis of its non-prospective nature, treatment of PAS with propofol CRI 428 
was not randomized in our study. Therefore, it is likely that it will have been administered to 429 
the most severely affected cases in our study. While there are reports of a more favorable 430 
prognosis with administration of propofol CRI,7,17,20 individual numbers are small and may 431 
represent a positive outcome publication bias. Previous studies have reported conflicting results 432 
regarding the possible protective effect of LEV against development of PAS.18,21,22,REDACTED 433 
Approximately half of the dogs in our study received prophylactic LEV. The recommended 434 
dose of LEV is 20 mg/kg per os every eight hours for a minimum of 24 hours preoperatively.27 435 
On the basis of the known pharmacokinetics of the drug (albeit in healthy dogs), continuation 436 
of the drug at the same dose during the first seven days postoperatively should be considered.28 437 
Several dogs in our study received less standardized protocols of LEV (groups LEV2 and 438 
LEV3). No group; however, was of prognostic significance. It is possible that dogs that develop 439 
PAS despite receiving prophylactic treatment with LEV are biased toward more severe post-440 
attenuation neurologic dysfunction, although this is purely speculative. It also raises the 441 
question whether continued treatment of such dogs with LEV following development of PAS 442 
is likely to be of benefit. 443 
 444 
This study has a number of important limitations. Like all retrospective studies, the accuracy 445 
of the presented data relies on the completeness of the medical records. Seventy-five of the 446 
dogs of the present report are the subject of another study which investigated the effect of 447 
prophylactic treatment with LEV on the incidence of PAS in dogs that underwent cEHPSS 448 
attenuation.REDACTED On the basis of the infrequent occurrence of PAS, the present study 449 
would not have been possible without the inclusion of such dogs. This was a multicenter 450 
study involving multiple surgeons, with differences in case management and experience in 451 
treating PAS. Treatment of PAS with different anti-epileptic drugs was not randomized but 452 
rather based on clinician preference. Drug dosages and infusion dose rates were not 453 
standardized. We did not record individual doses of various anti-epileptic drugs used to treat 454 
PAS as these will have varied widely even within individual dogs, with most dogs receiving 455 
numerous boluses of individual drugs along with variable rates of CRIs. Other factors 456 
including the attending clinician’s perception of prognosis for neurologic recovery following 457 
development of PAS, the extent to which the seizures were treated, cost of treatment and 458 
client willingness to treat seizures cannot be controlled due to the retrospective nature of the 459 
study. The authors acknowledge that several of the dogs included in this study may have 460 
experienced prodromal neurologic signs prior to seizure onset; however, due to its 461 
retrospective nature, the exact timing and details of such may not have been accurately 462 
recorded in the medical record. The classification of seizures as focal or generalized in this 463 
study reflects what was recorded in the medical record. Assignment of a dog as having 464 
experienced a seizure will have been based on the attending clinician’s/criticalist’s 465 
interpretation of the neurologic signs manifested. Importantly; however, all dogs were treated 466 
at academic teaching hospitals or referral institutions, by multidisciplinary staff with 467 
extensive experience in treating dogs with portosystemic shunts and their complications. 468 
Finally, just under 10% of dogs that experienced PAS in this study were not treated for PAS 469 
at the operating institution and the impact of this on the survival of such dogs is unknown.  470 
 471 
The overall short-term survival rate in this study was low, with just under one third of dogs 472 
surviving to 30 days. Affected dogs that had a history of preoperative seizures or experienced 473 
focal PAS only had significantly improved short-term survival. The results of this study will 474 
help in the counseling of owners who seek treatment for cEHPSS and may serve as a basis 475 
for further investigation regarding prevention or treatment of PAS in the future. 476 
 477 
 478 
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Table 1: Electrolyte, ammonia and glucose concentrations of all affected dogs (with results 611 
available), survivors and non-survivors, and dogs with and without a history of preoperative 612 
seizures. 613 



































































































































































Table 2: Results of univariable regression analysis of variables potentially associated with 616 
survival to 30 days. 617 
Abbreviations: LEV; levetiracetam. 618 






(n) P value 
Center      0.48 
       















 Shih Tzu 8 8.6 1 7  
 Maltese terrier 6 6.5 1 5  
 Pug 9 9.7 3 6  
 
Miniature 





terrier 6 6.5 
2 4 
 
 Dachshund 3 3.2 0 3  
 Chihuahua 4 4.3 1 3  
 
West Highland 





 Norfolk terrier 1 1.1 1 0  
 Border terrier 1 1.1 1 0  
 Brussels Griffon 1 1.1 0 1  
 Coton De Tulear 1 1.1 0 1  
 Setter 1 1.1 0 1  
       






















female 2 2.2 
1 1 
 
       







       







       










 Portophrenic 6 6.5 0 6  
 Unspecified 4 4.3 0 4  
       
Concurrent/historical 










       
Preoperative 










       










       
Preoperative 
antimicrobial(s) for 
minimum of one 














 Unknown 2 2.2 0 2  
       
Preoperative 
lactulose for 
minimum of one 














 Unknown 2 2.2 0 2  
       




















       
Year of surgery 2005 2 2.2 0 2 0.94 
 2006 3 3.2 2 1  
 2007 1 1.1 0 1  
 2008 5 5.4 1 4  
 2009 2 2.2 0 2  




















 2014 6 6.5 1 5  










 2017 3 3.2 1 2  
 2018 1 1.1 1 0  
       
Surgery from 
January 1st 2012 







 No 33 35.5 12 21  
       
Method of shunt 



















and thin film 






       
Degree of 
intraoperative 

















       











Table 3: Results of univariable analysis of drugs administered as part of treatment of PAS. 620 
Abbreviations: CRI: continuous rate infusion.  621 





(n) P value 
Propofol CRI Yes 49 52.7 12 37 0.21 
 No 43 46.2 18 25  
 Unknown 1 1.1 0 1  
       
Alfaxalone CRI Yes 3 3.2 0 3 1.0 
 No 89 95.7 30 59  
 Unknown 1 1.1 0 1  
       
Mannitol Yes 16 17.2 3 13 0.44 
 No 76 81.7 27 49  
 Unknown 1 1.1 0 1  
       
Benzodiazepine(s) Yes 45 48.4 11 34 0.27 
 No 47 50.5 19 28  
 Unknown 1 1.1 0 1  
       
Levetiracetam Yes 64 68.8 22 42 0.52 
 No 29 31.2 8 21  
       
Phenobarbital Yes 55 59.1 16 39 0.68 
 No 37 39.8 14 23  
 Unknown 1 1.1 0 1  
       
Potassium bromide Yes 13 14.0 7 6 0.23 
 No 79 85.0 23 56  
 Unknown 1 1.1 0 1  
       
Alpha-2 agonist Yes 8 8.6 4 4 0.56 
 No 84 90.3 26 58  
 Unknown 1 1.1 0 1  
       
Gabapentin/pregabalin Yes 4 4.3 2 2 0.45 
 No 88 94.6 28 60  
 Unknown 1 1.1 0 1  
       
Flumazenil Yes 2 2.2 2 0 0.98 
 No 91 97.8 28 63  
 Unknown 1 1.1 0 1  
       
Complication during 
treatment of post-







  No 77 82.8 28 49   
 622 
Table 4: Results of multivariable logistic regression model assessing relationship with 623 
outcome of survival to 30 days. 624 
Variable Category Odds Ratio 95% CI P-value 
Preoperative 
seizures 
Yes 7.6 1.9-30.3 0.004 
 No Ref   
     
Type of PAS Focal only 14.4 3.4-60.2 0.0003 
 Generalized +/- 
focal 
Ref   
 625 
Table 5: Reason for euthanasia, cause of natural death and complications during treatment of 626 
post-attenuation seizures. *Not recorded if died or euthanized (n=3), †Not recorded if died or 627 
euthanized (n=3). 628 
Cause of natural death* § Cardiorespiratory arrest (n=5) 
§ Aspiration pneumonia (n=1) 
§ Suspect cerebrocortical necrosis secondary to severe 
hypernatremia and hyperchloremia (n=1)	
§ Spontaneous death (n=1)	
§ Heart failure, pulmonary edema (n=1)	
Reason for euthanasia† § Uncontrolled or recurrent seizures (n=24)	
§ Persistent seizures and poor prognosis (n=8) 
§ Uncontrolled seizures +/- financial limitations to 
ascertain if seizures would eventually cease (n=5) 
§ Respiratory arrest (n=2) 
§ Poor mentation (n=1) 	
§ Blind, unable to stand, welfare concerns (n=1)	
§ Disorientated, vocalizing and non-responsive (n=1)	
§ Seizures, suspected aspiration pneumonia (n=1)	
§ Seizures, hypoventilation and poor prognosis (n=1)	
§ Seizures, unresponsive and fulminant liver failure (n=1)	
§ Suspected portal hypertension (n=1)	
§ Aspiration pneumonia (n=1)	
§ Uncontrolled neurologic signs (n=1)	
§ Uncontrolled seizures and pulmonary edema (n=1)	
§ Unsuccessful reanimation (n=1)	




§ Aspiration pneumonia (n=4)	
§ Pyrexia, respiratory arrest and aspiration pneumonia 
(n=1) 
§ Aspiration pneumonia and suspect thromboembolic 
event (n=1) 
§ Acute renal failure, cardiogenic edema and pneumonia 
(n=1) 
§ Repeated respiratory arrest (n=1)	
§ Hypoventilation requiring mechanical ventilation (n=1)	
§ Hypoventilation requiring mechanical ventilation, 
suspected vagal event (hypertension and tachycardia), 
respiratory arrest (n=1)	
§ Fulminant liver failure (n=1)	
§ Hyperthermia, tachycardia, hematochezia suspected 
related to portal hypertension (no mesenteric congestion 
at revision coeliotomy) (n=1)	
§ Sepsis suspected to be associated with gastrostomy tube 
(n=1)	
§ Sepsis, systemic inflammatory response syndrome, 
disseminated intravascular coagulation, suspect 
pneumonia, requirement for mechanical ventilation 
(n=1)	
§ Pulmonary edema (n=1)	
§ Pulmonary edema, hypothermia and hyperthermia (n=1)	
 629 
